Navigation Links
Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
Date:5/29/2008

WOODCLIFF LAKE, N.J., May 29 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that its development partner, Alfacell Corporation (Nasdaq: ACEL) reported that the preliminary statistical analysis of data from its confirmatory Phase IIIb clinical trial of its lead compound, ONCONASE (ranpirnase), did not meet statistical significance for the primary endpoint of survival in unresectable malignant mesothelioma (UMM). However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen.

The preliminary results are based on 320 evaluable events that occurred in the clinical trial out of a total of 428 patients randomized. The trial was designed to show a statistically significant improvement in overall survival (p < 0.048) for UMM patients who were treated with a combination of ONCONASE plus doxorubicin as compared to patients who were treated with doxorubicin as a single agent. The analysis of the data did not show a statistically significant improvement for evaluable patients receiving ONCONASE plus doxorubicin (unadjusted log rank p=0.80). The median survival time (MST) for evaluable patients who received ONCONASE plus doxorubicin was 11.1 months as compared to 10.7 months for patients who received doxorubicin as a single agent.

Statistically significant results were achieved in evaluable UMM patients who failed a prior chemotherapy
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
2. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
3. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
6. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
7. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
(Date:8/28/2015)... Aug. 28, 2015 Perrigo Company plc ("Perrigo") ... Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote ... "Our views of Mylan,s offer to Perrigo shareholders ... on our Board,s careful reflection of the value available ... limited choices that Mylan has allowed its shareholders to ...
(Date:8/28/2015)... HERTFORDSHIRE, England and PITTSBURGH ... (NASDAQ: MYL ) today announced that its ... Company plc (NYSE: PRGO ; TASE) and ... Perrigo,s shareholders at an extraordinary general meeting of ... of two-thirds of the votes cast at the extraordinary general ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... ADDISON, Texas and SALT LAKE CITY, Feb. 28, 2011 ... HUM ), is transforming the future of occupational ... improvements, creating exceptional and engaging experiences for clients and ... Concentra has joined the ranks of top U.S. consumer ...
... 28, 2011 ViroPharma Incorporated (Nasdaq: VPHM ) ... of ViroPharma, will present at the Citi 2011 Global Healthcare ...  The conference is being held at the Hilton New York ... president and chief financial officer, of ViroPharma, will present at ...
Cached Medicine Technology:Concentra is Writing a New Prescription on Health Care With Outstanding Service 2Concentra is Writing a New Prescription on Health Care With Outstanding Service 3Concentra is Writing a New Prescription on Health Care With Outstanding Service 4Concentra is Writing a New Prescription on Health Care With Outstanding Service 5ViroPharma to Participate in Two March Healthcare Conferences 2
(Date:8/30/2015)... ... August 30, 2015 , ... InHealth Media ( http://www.inhealthmedia.com ... Global Communications Director for InHealth Media. Mr. Spector comes with a wide ... years doing on-air television, producing shows, on air-radio and media relations. , ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... medical devices for the treatment of prostate cancer, has announced the roll-out of ... at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I have ... Miller Place, N.Y. "I specialize in manual therapy, and my invention will provide ... be used for additional muscle dysfunction throughout the body." , They developed THE ...
(Date:8/29/2015)... ... 2015 , ... Next weekend is Labor Day weekend, the last bash of ... 22nd this year). For IT security personnel, it should also mark the perfect time ... more costly than a simple headache. , Joe Caruso, founder and CEO-CTO of ...
(Date:8/29/2015)... ... 29, 2015 , ... Vascular Health Sciences announced today that ... Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. , ... in the United States District Court for the Southern District of Texas for ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
... ,Genzyme Corporation (Nasdaq: GENZ ) and Bioenvision, ... Bioenvision stockholders have voted to,approve the acquisition of ... meeting in New York. The transaction will be ... the company will,be delisted from Nasdaq. Fifty-six ...
... Vanda Pharmaceuticals,Inc. (Nasdaq: VNDA ) announced today ... of iloperidone at the 57th American Society of ... San Diego, CA, from October 23,through October 27, ... filing for iloperidone on September 27, 2007. Iloperidone ...
... evacuees to register on Safe and Well Website, ... California, forcing thousands to evacuate the area. During this,ongoing ... may feel confused,and anxious about the safety of their ... all those who have evacuated or who expect to,evacuate ...
... A team of Johns Hopkins scientists reports in this weeks ... that humans can be protected against the damaging effects of ... our environment by topical application of an extract of ... by parallel evidence obtained in mice, show that the degree ...
... 22 Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: ... (ADHD), announced today that it will present key,scientific ... scientific and,educational meeting of child and adolescent psychiatrists ... Shire studies to be presented are indicative of ...
... 22 HealthShares(TM) Inc., an investment,company with a series ... informed by Standard & Poor,s, the calculating agent for ... on,Thursday October 25, 2007, Amag Pharmaceuticals (Nasdaq: AMAG ... the HealthShares(TM) Diagnostics Index, and,Hologic Inc. (Nasdaq: HOLX ...
Cached Medicine News:Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 2Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 3Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4Health News:Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting 2Health News:Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting 3Health News:Southern California Wildfires Continue to Threaten Residential Areas 2Health News:Southern California Wildfires Continue to Threaten Residential Areas 3Health News:Broccoli sprout-derived extract protects against ultraviolet radiation 2Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 2Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 3Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 4Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 5Health News:HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes 2Health News:HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes 3
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Molt 9, excellent for subperiosteal tunneling....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Medicine Products: